血清CA153、CA125和CEA联合检测在乳腺癌诊断中的应用

Clinical application of combined detection of serum CA153,CA125 and CEA in doagnosis of breast cancer

目的探讨检测外周血肿瘤标志物CA153、CA125和CEA在乳腺癌的临床应用价值。方法应用电化学发光技术检测20例健康对照者、55例乳腺癌患者以及20例乳房良性肿瘤患者手术前、后血清中CA1 53、CA125和CEA含量。结果乳腺癌患者组血清CA153、CA125、CEA含量较健康对照组显著升高(P<0.05),其中CEA和CA153含量较乳房良性肿瘤患者组显著升高(P<0.05)。手术后,患者血清中CA153含量较手术前明显下降,差异具有统计学意义(P<0.05)。临床分期为Ⅲ、Ⅳ期的乳腺癌患者外周血CEA和CA153含量较健康对照组显著升高(P<0.05);Ⅲ、Ⅳ期的乳腺癌患者外周血CA153含量较Ⅰ、Ⅱ期患者显著升高(P<0.05)。联合检测CA153、CA125、CEA,敏感性达53.8%,特异性为83.3%。结论检测CA1 53、CA125、CEA对乳腺癌的诊断有一定的价值,其中CA153和CEA对良、恶性乳腺肿瘤的鉴别诊断、乳腺癌病情进程的监测有实用价值。

Objective To study the clinical singificance of serum tumor markers （CA153, CA125 and CEA） in doagnosis of breast cancer. Methods Electrochemiluminescence immunoassay （ECLIA） was used to analyze serum levels of CA153,CA125 and CEA in 55 patients with breast cancer （breast cancer group） ,20 patients with benign breast lesions （benign breast lesion group） and 20 healthy controls （healthy control group）. Results The levels of CA153,CA125 and CEA in breast cancer group were significantly higher than those in healthy control group （P〈0.05） ; the levels of CEA and CA153 in breast cancer group were significantly higher than those in benign breast lesion group （P〈0.05） ; the level of CA153 in postoperative patients was statistically lower than that in preoperative patients （P〈0.05） ; the levels of CEA and CA153 in breast cancer patients with stage and Ⅳ were significantly higher than those in healthy controls （P〈0.05）; the level of CA153 with stage Ⅲ and Ⅳ was higher than that in ones with stage Ⅰ and Ⅱ. The combined dection of CA153, CA125 and CEA in breast cancer patients increased the experimental sensitivity to 53.8 % and specificity to 83. 3%. Conclusion Detections of CA153, CA125 and CEA contribute to diagnosis of breast cancer. CA153 and CEA are of clinical practical value in differential diagnosis of benign and malignant breast tumor,monitoring of course of breast cancer.